Tipping P G, Holdsworth S R
Nephron. 1986;43(4):258-64. doi: 10.1159/000183851.
The efficacy of fibrinolytic therapy with streptokinase was assessed in rabbits developing anti-glomerular basement membrane antibody induced glomerulonephritis. Untreated animals developed renal failure (mean creatinine 615 +/- 120 microM/l) and a severe glomerulonephritis with prominent fibrin deposition. Streptokinase treatment of animals with established disease (creatinine 204 +/- 35 microM/l) reduced renal impairment (creatinine 256 +/- 68 microM/l, p less than 0.025) and fibrin deposition. Treatment of more advanced disease (creatinine 416 +/- 68 microM/l) did not preserve renal function (creatinine, 518 +/- 106 microM/l), although glomerular fibrin deposition was reduced. These studies indicate that fibrinolytic therapy with streptokinase reduces glomerular fibrin deposition and, if used early, protects from loss of renal function.
在发生抗肾小球基底膜抗体诱导的肾小球肾炎的兔子中评估了链激酶溶栓治疗的疗效。未经治疗的动物出现肾衰竭（平均肌酐615±120微摩尔/升）和伴有显著纤维蛋白沉积的严重肾小球肾炎。对已患疾病（肌酐204±35微摩尔/升）的动物进行链激酶治疗可减轻肾功能损害（肌酐256±68微摩尔/升，p<0.025）并减少纤维蛋白沉积。对更晚期疾病（肌酐416±68微摩尔/升）进行治疗虽然肾小球纤维蛋白沉积减少，但并未保留肾功能（肌酐518±106微摩尔/升）。这些研究表明，链激酶溶栓治疗可减少肾小球纤维蛋白沉积，并且如果早期使用，可防止肾功能丧失。
